BioVex
Oxton · Founded 1999
About BioVex
BioVex is a biotechnology company focused on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. Their cancer program, OncoVEXGM-CSF, is a oncolytic vaccine or cancer destroying virus technology that works by replicating and spreading within solid tumors, causing the death of cancer cells while leaving surrounding healthy cells unharmed. The attenuated virus has also been constructed to induce a powerful systemic anti tumor immune response. OncoVEXGM-CSF has now been tested in >110 patients in a broad range of solid tumors including melanoma, head & neck cancer, breast cancer and pancreatic cancer. Both the direct cell killing and systemic immune mediated mechanisms of action of OncoVEX have been clearly validated in the clinic; OncoVEX routinely destroys tumors it is directly injected into and has led to overall disease responses in multiple patients in Phase II testing. Tumors resolved through OncoVEX treatment have not been known to recur.
Company Facts
- Founded: 1999
- Legal name: BioVex Group Inc.
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $128.4M
- Funding stage: M&A
- Last round: Series Unknown (Mar 2009)
- Website: biovex.com
- Phone: +4401235441900
Social Profiles
Canonical: https://fsome.com/organization/biovex-8424061 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.